Key result
Plasma extracellular vesicles are a novel source of blood-based biomarkers with the potential to improve the diagnosis and prognosis of cardiovascular disease.
Plasma extracellular vesicles hold promise as novel biomarkers for cardiovascular disease diagnosis and prognosis, highlighting the need for improved isolation technologies to enable clinical translation.
Cardiovascular disease (CVD) is the leading cause of death worldwide and its prevalence is expected to rise rapidly worldwide in the coming decades. Atherosclerosis, the syndrome underlying CVD, is a chronic progressive disease of the arteries already present at a young age. Strokes, heart attacks and heart failure are acute CVD events that occur after decades, however, and require timely diagnosis and treatment. Plasma extracellular vesicles (EVs) are microstructures with a lipid bilayer membrane involved in hemostasis, inflammation and injury. Both EV-counts and EV-content are associated with CVD and the identification of plasma EVs is a novel source of blood-based biomarkers with the potential to improve diagnosis and prognosis of CVD. Presented in this review is an overview of the current use of EVs in CVD and a discussion of the need for robust and easy isolation technologies for plasma EV subsets. This is needed to bring this promising field towards clinical application in the patient.
No takes yet. Share an insight, caveat, or question.
Bank et al. (2015) conducted a review in Cardiovascular disease. Plasma extracellular vesicles was evaluated. Plasma extracellular vesicles are a novel source of blood-based biomarkers with the potential to improve the diagnosis and prognosis of cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: